Your Best Stock

Sanofi SNY

US equityMarket cap rank #161Infectious Disease
$41.00
−$0.66 (-1.58%)
Market open · Sep 24, 2:00 pm ET
After hours $41.66 0.00%
Open$41.24
Prev close$41.66
Day range$40.93 – $41.61
Volume1.99M
Market cap$98.24B
P/E (TTM)22.0
Dividend yield5.77%

Earnings

Average move on report day±3.2%last 15 reports
Closed higher9 of 1560% of the time
Best reaction+5.9%
Worst reaction-7.3%

Stock move on the day after each report

-2.0%2023/Q2-3.0%2023/Q4+5.9%2024/Q1+3.7%2024/Q2+4.4%2024/Q3+3.8%2024/Q4+1.0%2025/Q1-7.3%2025/Q2+4.3%2025/Q3+0.9%2025/Q4+1.3%2026/Q1-4.4%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q330 Oct 2026Pre Market–––
2026/Q230 Jul 2026Pre Market±1.9%-4.37%Bigger than priced
2026/Q123 Apr 2026–±3.1%+1.34%Within range
2025/Q429 Jan 2026Pre Market±3.1%+0.94%Within range
2025/Q324 Oct 2025–±2.2%+4.28%Bigger than priced
2025/Q231 Jul 2025–±2.9%-7.33%Bigger than priced
2025/Q124 Apr 2025–±4.2%+0.98%Within range
2024/Q430 Jan 2025Pre Market±3.4%+3.84%Bigger than priced
2024/Q325 Oct 2024Pre Market±3.3%+4.40%Bigger than priced
2024/Q225 Jul 2024–±4.0%+3.71%Within range
2024/Q125 Apr 2024–±4.1%+5.90%Bigger than priced
2023/Q41 Feb 2024Pre Market±3.5%-2.99%Within range
2023/Q228 Jul 2023Pre Market±3.6%-1.98%Within range
2023/Q127 Apr 2023–±4.1%-0.23%Within range
2022/Q43 Feb 2023Pre Market±2.8%-2.58%Within range
2022/Q328 Oct 2022–±2.9%+3.54%Bigger than priced

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q2

By business line

  • BioPharma€21.14B 99.0%
  • Other€206.00M 1.0%

Latest reported quarter: Q2, ended Jun 2026 · reported in EUR

Revenue€12.30B+14.6% YoY
Operating profit€2.38B+22.9% YoY
Net profit€377.00M-90.4% YoY
Diluted EPS€0.14-91.2% YoY
Free cash flow€1.66B+3,861.9% YoY
Operating cash flow€2.96B

Revenue, last 8 quarters

€13.0BSep '24€11.4BDec '24€10.6BMar '25€10.7BJun '25€13.2BSep '25€12.2BDec '25€11.2BMar '26€12.3BJun '26

Net profit, last 8 quarters

€2.8BSep '24€511.0MDec '24€1.9BMar '25€3.9BJun '25€2.8BSep '25€-794.0MDec '25€1.6BMar '26€377.0MJun '26

Profitability & balance sheet

Gross margin72.8%
Operating margin20.6%
Net margin8.1%
Return on equity5.7%
Return on assets3.1%
Return on invested capital4.7%
Current ratio0.99
Liabilities / assets46.1%
Cash & investments€6.35B
Total debt€23.35B
Net cash (debt)-€17.00B
Free cash flow / sales17.2%
Scroll to Top